<DOC>
	<DOCNO>NCT01235520</DOCNO>
	<brief_summary>This randomize , multi-center , double-blind , parallel-group , placebo-controlled study evaluate efficacy safety RO4917838 patient sub-optimally control symptom schizophrenia . Patients , stable treatment antipsychotic , randomize receive daily oral dos RO4917838 match placebo 52 week , follow optional treatment extension 3 year .</brief_summary>
	<brief_title>A Study RO4917838 Patients With Sub-optimally Controlled Symptoms Schizophrenia ( NN25307 )</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Diagnosis schizophrenia Clinical stability 16 week ( 4 month ) prior randomization Antipsychotic treatment stability past 12 week prior randomization With exception clozapine , patient available marketed atypical typical antipsychotic ( treatment maximum two antipsychotic ) Has treatment resistant schizophrenia judge treat physician OR fail two trial Evidence patient clinically significant uncontrolled unstable medical disorder ( e.g . cardiovascular , renal hepatic , gastrointestinal , hematologic , immunological , neurological , endocrine , metabolic pulmonary disease ) Patient body mass index ( BMI ) &lt; 17 &gt; 40 kg/m2 , respectively Diagnosis mental retardation severe organic brain syndrome In investigator 's judgment , significant risk suicide violent behavior</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>